Hanson Pharmaceuticals (03692): The treatment of osteosarcoma with Ruikang rivoltamab (HS-20093) for injection is included in the priority review and approval process of the State Drug Administration

According to Zhitong Finance App, Hanson Pharmaceuticals (03692) announced that on September 14, 2026, based on the positive results of the HS-20093 (injectable Ruikang rivolutamab) (this product) (this product) key phase III trial, the indications for the treatment of osteosarcoma patients aged ≥12 years who have failed at least second-line treatment were included in the China National Drug Administration (NMPA) priority review and approval process.